GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (NAS:APLS) » Definitions » 50-Day SMA

APLS (Apellis Pharmaceuticals) 50-Day SMA : $29.41 (As of Dec. 13, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Apellis Pharmaceuticals 50-Day SMA?

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2024-12-13), Apellis Pharmaceuticals's 50-Day SMA is $29.41. It's 20-Day SMA is $31.78 and 200-Day SMA is $39.95.


Competitive Comparison of Apellis Pharmaceuticals's 50-Day SMA

For the Biotechnology subindustry, Apellis Pharmaceuticals's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apellis Pharmaceuticals's 50-Day SMA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apellis Pharmaceuticals's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Apellis Pharmaceuticals's 50-Day SMA falls into.



Apellis Pharmaceuticals  (NAS:APLS) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apellis Pharmaceuticals  (NAS:APLS) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.


Apellis Pharmaceuticals 50-Day SMA Related Terms

Thank you for viewing the detailed overview of Apellis Pharmaceuticals's 50-Day SMA provided by GuruFocus.com. Please click on the following links to see related term pages.


Apellis Pharmaceuticals Business Description

Traded in Other Exchanges
Address
100 Fifth Avenue, Waltham, MA, USA, 02451
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Executives
James George Chopas officer: See Remarks 950 WINTER STREET, WALTHAM MA 02451
A. Sinclair Dunlop director C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Pascal Deschatelets officer: Chief Operating Officer 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Timothy Eugene Sullivan officer: Chief Financial Officer 800 BOYLSTON ST., SUITE 3310, PRUDENTIAL TOWER C/O AJU IB INVESTMENT, BOSTON MA 02199
Mark Jeffrey Delong officer: Senior Vice President 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Nur Nicholson officer: Chief Technical Officer APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Cedric Francois director, 10 percent owner, officer: Chief Executive Officer 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Adam J. Townsend officer: See Remarks C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
David O. Watson officer: General Counsel 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Karen Lewis officer: Chief People Officer APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Jeffrey Eisele officer: See Remarks APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Caroline Baumal officer: Chief Medical Officer C/O APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Lukas Scheibler officer: See Remarks C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Alec Machiels director 505 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10022
Federico Grossi officer: See Remarks C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014